Pfizer’s Diminished Expectations For Insulin Biosimilar Market Likely Scuttled Partnership With Biocon
This article was originally published in PharmAsia News
Executive Summary
Pfizer and India’s Biocon called off their four-product diabetes biosimilar partnership on March 12, with Biocon keeping more than $100 million realized over the life of the deal and regaining all product IP.